Biomarkers of cardiac disease.
The challenge of medical practice today is to identify individuals who are at risk of developing disease, determine the severity of the disease and distinguish the responders from the nonresponders to therapy (individualized medicine). Advances in molecular genetics and biology have shifted the paradigm for identification of markers from large-scale epidemiologic studies to studies on genomic- and proteomic-based techniques. Consequently, a large number of biologic markers, referred to as biomarkers, are being identified and validated to serve for risk stratification, prognostication and individualization of therapy. Identification of biomarkers for cardiovascular diseases could also provide insight into the pathogenesis of the phenotype, which is fundamental for the development of specific therapies. The list of biomarkers for cardiovascular disease is expanding rapidly. Nonetheless, the field is in the early stages of evolution and large-scale clinical studies are required to validate the utility of newly identified biomarkers in diagnosis, risk stratification and treatment of cardiovascular diseases. Selected biomarkers for coronary atherosclerosis, acute coronary syndromes and heart failure are discussed in this review.
Marian
A J
AJ
Baylor College of Medicine, One Baylor Plaza, 519D, Houston, TX 77030, USA. amarian@bcm.tmc.edu
Nambi
Vijay
V
D015415:Biomarkers; D006331:Heart Diseases / Q000175:diagnosis* / Q000628:therapy*; D006801:Humans; D011379:Prognosis
D015415:Biomarkers